RSS feed

Publications (original articles or review articles) published in 2018 from OUS - Department of Clinical Cancer Research

18 publications found

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET (2018)
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Med Oncol, 35 (4), 47
DOI 10.1007/s12032-018-1103-x, PubMed 29511910

Bjørnelv GMW, Dueland S, Line PD, Joranger P, Fretland ÅA, Edwin B, Sørbye H, Aas E (2018)
Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver
Br J Surg, 106 (1), 132-141
DOI 10.1002/bjs.10962, PubMed 30325494

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
Transl Oncol, 12 (1), 76-83
DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860

Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL (2018)
Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer
Clin Chim Acta, 487, 107-111
DOI 10.1016/j.cca.2018.09.029, PubMed 30240586

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Eur J Cancer, 101, 236-243
DOI 10.1016/j.ejca.2018.06.034, PubMed 30096704

Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JEA, Bastiaannet E, van de Velde CJH (2018)
North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis
Eur J Surg Oncol, 44 (12), 1982-1989
DOI 10.1016/j.ejso.2018.09.014, PubMed 30343998

Dueland S, Foss A, Solheim JM, Hagness M, Line PD (2018)
Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma
Br J Surg, 105 (6), 736-742
DOI 10.1002/bjs.10769, PubMed 29532908

Dueland S, Line PD, Hagness M, Foss A, Andersen MH (2018)
Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver
BJS Open, 3 (2), 180-185
DOI 10.1002/bjs5.50116, PubMed 30957065

Grut H, Revheim ME, Line PD, Dueland S (2018)
Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation
Nucl Med Commun, 39 (7), 621-627
DOI 10.1097/MNM.0000000000000843, PubMed 29683930

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV (2018)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
J Clin Oncol, 36 (35), 3441-3449
DOI 10.1200/JCO.18.01219, PubMed 30343620

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
DOI 10.1038/s41416-018-0085-y, PubMed 29695770

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W, Donica M, Makrutzki M, Blank C (2018)
An open-label, multicentre safety study of vemurafenib in patients with BRAF^V600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
Eur J Cancer, 107, 175-185
DOI 10.1016/j.ejca.2018.11.018, PubMed 30580112

Line PD, Hagness M, Dueland S (2018)
The Potential Role of Liver Transplantation as a Treatment Option in Colorectal Liver Metastases
Can J Gastroenterol Hepatol, 2018, 8547940
DOI 10.1155/2018/8547940, PubMed 29623266

Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG (2018)
Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
Eur J Surg Oncol, 44 (8), 1226-1232
DOI 10.1016/j.ejso.2018.03.029, PubMed 29691115

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S et al. (2018)
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
Ann Oncol, 29 (3), 758-765
DOI 10.1093/annonc/mdx774, PubMed 29216400

Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ (2018)
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'
Eur J Cancer, 94, 156-167
DOI 10.1016/j.ejca.2018.02.011, PubMed 29567632

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH (2018)
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Anticancer Res, 38 (2), 871-876
DOI 10.21873/anticanres.12296, PubMed 29374714